Brand Change: fulvestrant inj 50 mg per ml, 5 ml prefilled syringe

Kia ora

We are writing to inform you of a brand change.

Key Dates:

• Fulvestrant EVER Pharma brand of fulvestrant inj 50 mg per ml, 5 ml prefilled syringe will be listed (funded) on the Pharmaceutical Schedule from 1 December 2025.

• Fulvestrant EVER Pharma will be awarded Principal Supply Status (the main funded brand) from 1 May 2026 to 30 June 2028.

• The current brand Faslodex will be delisted (no longer funded) 1 May 2026.

Key Messages:

• Fulvestrant EVER Pharma is currently being supplied to the Australian market.

• There have been no identifiable concerns raised with the generic fulvestrant products in Australia.

• The Exceptional Circumstances pathway for consideration of funding an alternate brand is available for those patients who are unable to make the transition for clinical reasons.

• Fulvestrant EVER Pharma has a non-refrigerated storage requirement - store at room temperature below 25^oC until ready for use. Store in the original package.  This may be an advantage for some people. Faslodex must be stored in the fridge.

More information and support for patients, including a downloadable patient leaflet, can be found here - Fulvestrant on Pharmac website and on the Healthify webpage external link. 

Questions: 

If you have any queries, please contact us at enquiry@pharmac.govt.nz.

Please share this information:

Please share this information with your colleagues and within your networks.

If you no longer wish to receive emails from the Pharmac Implementation Team, please send a reply email with UNSUBSCRIBE in the subject heading. Thank you.

Ngā mihiDr David Hughes

David Hughes

Chief Medical Officer | Director Advice & Assessment

________________________________________________________________________________

Pharmac | Te Pātaka Whaioranga | PO Box 10 254 | Level 9, 40 Mercer Street, Wellington

DDI: +64 21 962 317 | P: +64 4 460 4990 |  www.pharmac.govt.nz